Nadh composition having antioxidant properties

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

 

The invention relates to the field of chemical-pharmaceutical and food industries, as well as to the field of cosmetology.

Real life conditions (stress, lack of sleep, environmental pollution, poor diet, bad habits and lifestyle, such as Smoking, alcohol, etc.) lead to the fact that their own body cannot replenish enough energy. Therefore, there is a proliferation of different energy pharmaceutical compositions and dietary supplements.

Important role in the body, namely in its energy metabolism performs a nicotinamide adenine dinucleotide (NAD, NAD). NAD is a coenzyme present in all living cells, which is part of the group of enzymes dehydrogenases that catalyze redox reactions and acts as a carrier of electrons and hydrogen, which takes away from oxidizable substances. The reduced form of the coenzyme (NADH or Coenzyme 1) is the metabolically active form of vitamin B3.

Deficiency of NADH is manifested in physical or mental fatigue. On the other hand, the more NADH available to the cell, the more energy it can produce. With increasing age the body's production of NADH increases markedly.

NADH was opened in 1905 And only in the 80-ies managed to create a form suitable for eg� oral administration. This is due, in particular, and with the fact that NADH is extremely unstable in its chemical composition from nature. Under the action of oxygen and light, this vitamin can very quickly lose its effectiveness.

Known therapeutic composition according to the patent US 5332727, publ. 26.07. 1994. A composition in the form of tablets, coated with acid-resistant coating, which contain from 3 to 10% by weight of NADH or NADPH, or a physiologically acceptable salt, 1 to 10% by weight of a stabilizer selected from the group consisting of NaHCO3, ascorbic acid, sodium ascorbate, tocopherol, tocopherol acetate and polyvinylpyrrolidone, and a filler selected from the group comprising mannitol, microcrystalline cellulose, carboxymethyl cellulose and dibasic calcium phosphate. The storage stability is achieved through the shell.

From patent US 6500451 (B2), publ. 2002-12-31, known pills energy supplements containing NADH, octacosanol, vitamin E, vegetable magnesium stearate, microcrystalline cellulose, hydrated silicon dioxide and dibasic calcium phosphate. Tablets may also require protective coatings.

As the closest analogue (prototype) can be specified composition with antioxidant properties, prolonged release of many particles with enteric coating�education, containing NADH, PVP, ethanol, vitamin E, microcrystalline cellulose, starch (EP 1346723 (A1), publ. 2003-09-24).

The object of the present invention is to provide a new pill form of NADH, manifesting its properties during intragastric taken in the form of a complex that protects the active substance from the destructive action of the enzymes of the mouth, stomach acid and other factors, decontamination NADH.

The problem is solved by the composition of the tablets, stable, but not coated, which includes the active principle in the composition of the complex which is a blend of 10 wt.% reduced forms of nicotinamide adenine dinucleotide (NADH) with 63 wt.% vegetable fats, 17 wt.% beeswax and 10 wt.% chlorophyll, and as the inert filler is microcrystalline cellulose, macrogol 6000, intense sweetener, a flavor, with the following content of components, mass.%:

the active principle in the form of the complex10-35
microcrystalline cellulose50-90
Macrogol 60000,05-4,5
sweetener0,01-2,5
and�amatista of 0.01-5

As an intensive sweetener can be used aspartame, stevioside, saccharin, Acesulfame-K and similar.

As a food flavoring can be used any neutralnie or identical to natural flavourings type "Sweet Apple", "Raspberry", "Apricot", "Vanilla cream", etc. Most preferred the taste gives a flavor "Sweet Apple".

Tablet NADH contains one active ingredient: dietary nicotinamide adenine dinucleotide (NADH), which are presented as part of the complex which is a blend in naturally acid-stable form - PANMOL®-NADHmicro, containing in wt.%:

10% NADH;

63% vegetable fat;

17% beeswax;

10% chlorophyll.

Vegetable oils can be selected from edible oils such as pine, linseed, soya, etc., and may also represent the glycerides of acids of vegetable origin, such as palmitic, oleic or linoleic.

The complex may constitute microcapsules with an average size of 100-200 μm. Microcapsules can optionally be coated with enteric coating.

The invention can be illustrated by the following example.

Example 1

MANUFACTURING PROCESS

All ingredien�s weigh:

PANMOL®-NADHmicro72,000 kg
Microcrystalline cellulose276,480 kg
Macrogol 60002,880 kg
Aspartame1,440 kg
Flavor "Sweet Apple"7,200 kg

Next, each ingredient sieved using a mesh filter (0.5±0.05 mm) and mixed in a mixer Servolift MC (capacity maximum mixing drum 500 kg - diffusion mixer)

The order of addition to the mixing drum:

1. Microcrystalline cellulose200,000 kg
2. PANMOL®-NADHmicro72,000 kg
3. Flavor "Sweet Apple"7,200 kg
4. Aspartame1,440 kg
5. Macrogol 60002,880 kg
6. Microcrystalline cellulose76,480 kg

The process parameters smash�tion:

the mixing speed11
rpm the mixing time50 minutes

Then the resulting mixture is compressed using rotational tablet press for pressing tablets KILIAN S250 SMART. The weight of the 20 tablets of 5.0 g±5%. The average weight of the tablets 250 mg±5%. Height pills 3.4±0.5 mm. the Hardness is not less than 50 N and not more than 120 N.

Each tablet contains:

250,0 mg
PANMOL®-NADHmicro (equivalent adenine dinucleotide (NADH))50.0 mg20%
Excipients:
Microcrystalline cellulose192,0 mg76,8%
Macrogol 60002.0 mg0,8%
Aspartame1.0 mg0,4%
Flavor "Sweet Apple"5.0 mg2,0%
The total number of100%

Tablets NADH round, unpainted, white or close to white or cream color with occasional black-and-green patches with a diameter of preferably 9 mm. the tablet Form - with flat top surface with beveled edges and an average weight of 250 mg.

The disintegration time is not more than 15 minutes.

During the process of tableting appearance, average weight and a hardness of 20 tablets monitor every 20 minutes. Information corresponding to the technological process (the time and date of production and manufacturing operations, the number of batches of raw materials and the raw materials, the number of tablet mixture and the weight of the tablets, the appearance of tablets, the average weight and height of the tablets), recorded in the Protocol of the party according to the instructions.

The tablets are Packed in labeled primary packaging - blisters (10 tablets per blister).

Shelf life of not less than 2.5 years.

Received tablet form of NADH shows its properties in intragastric taken in the form of a complex that protects the active substance from the destructive action of the enzymes of the mouth, stomach acid and other factors, decontamination NADH.

Welcome new tableted form of NADH promotes:

- to raise the level bokstav�Oia;

- improved ability to concentrate and hold attention;

- prevention of fatigue and maladjustment when changing time zones.

- increase daily productivity and viability;

- the prevention of disorders of memory, attention and other aspects of cognitive functioning of various origins, including exclusion related to stress;

- normalize mood swings of various origins;

- improvement of asthenia any Genesis;

as part of complex therapy to improve conditions in chronic fatigue syndrome, Parkinson's disease, Alzheimer's disease, fibromalgia, signs of aging, the metabolic syndrome, including hypercholesterinemia and hypertension, depression of various origins, various conditions associated with decreased immunity.

Composition with antioxidant properties, in the form of pills containing the active principle on the basis of nicotinamide adenine dinucleotide in reduced form (NADH) and inert fillers, characterized in that it comprises the active principle in the composition of the complex which is a mixture of 10 wt.% NADH from 63 wt.% vegetable fats, 17 wt.% beeswax and 10 wt.% chlorophyll, and as the inert filler is microcrystalline cellulose, macrogol 6000, intense sweeten�ü, food flavour, with the following content of components, mass.%:

the active principle in the form of the complex10-35
microcrystalline cellulose50-90
Macrogol 60000,05-4,5
sweetener0,01-2,5
flavoringof 0.01-5



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.

EFFECT: realisation of the claimed purpose.

1 dwg

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-2-chloro-benzimidazole of formula (I) as the preparation, inhibiting peroxide oxidation of lipids.

EFFECT: achievement of the claimed purpose, activity of the said formula compound is higher than of the comparison medication dibazole.

1 dwg

FIELD: medicine.

SUBSTANCE: method for preparing an agent possessing anti-inflammatory, diuretic and antioxidant activity, involving milling Spiraea salicifolia shoots representing a mixture of leaves, blossom and shoots, extracting them three times by gradual maceration, mixing in infusing, filtering, condensing, separating, drying in the certain environment.

EFFECT: agent shoes the pronounced anti-inflammatory, diuretic and antioxidant activity.

2 dwg, 12 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and can be used as a hepatotrophic, lipotropic agent in gastroenterology, as well as for treating cardiac and cerebral atherosclerosis, in neurology in the lower extremity artery diseases (endarteritis). The agent contains tabletted powders of diisopropylammonium dichloroacetate, microcrystalline cellulose, lactose and excipients presented by Aerosil, Primogel and calcium stearyl fumarate.

EFFECT: agent possesses no toxicity, has the high adsorption properties, the apparent anti-inflammatory action, and provides metabolism and the liver regeneration.

3 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to heterocyclic compound - 6-methyl-5-morpholynomethyl-1-(thiethan-3-yl)pyrimidine-2,4(1H,3H)-dione of formula 6-methyl-5-morpholynomethyl-1-(thiethan-3-yl)pyrimidine-2,4(1H,3H)-dione of formula: .

EFFECT: novel compound, possessing antioxidant activity, is obtained.

2 cl, 6 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.

EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.

6 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.

EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.

7 cl, 1 ex

FIELD: food industry.

SUBSTANCE: biologically active food additive strengthening the organism adaptive power and body defences and having anti-inflammatory and antioxidant activity contains vegetal origin components represented by a complex extract of devil's-club root, Rhaponticum carthamoides root, Hedysarum neglectum Ledeb root, celery roots and leaves, rhodiola rosea root, Japanese angelica tree roots, boschniakia rossica roots, Hungarian sainfoin herb, magnolia-vine fruits; additionally the additive contains chitosan, trepang fermentative hydrolysate, ascorbic acid, taurine, glutathione, nicotinamide, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, anhydrous calcium chloride, magnesium chloride, zinc chloride, bee honey at preset ingredients ratio.

EFFECT: biologically active food additive promotes effective strengthening of the organism adaptive power and body defences and human aging retardation.

4 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical radiology and can be used for prevention of cerebral form of acute radiation sickness. Claimed is application of officinal drug pyrazinamide as medication for prevention of cerebral form of acute radiation sickness. Pyrazinamide has been used for treating tuberculosis.

EFFECT: preventing in 100% of cases development of early temporary incapacity in case of irradiation in dose 200 Gy, improvement of indices of behavioral and research activities in irradiated animals, in reduction of frequency of motor disorders, reduction of frequency and expression of convulsive-hyperkinetic syndrome and 9,5 fold increase of average life expectancy of irradiated animals Pyrazinamide is not inferior to drug - nicotinamide prototype in efficiency of radioprotective action.

4 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: as active component pharmaceutical composition contains dihydrochloride of 9-(2-morpholine ethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidasol, and as additional substances - fillers, binding, sliding and film coatings, in quantities, given in the invention formula. Composition can be made in form of solid medication form, mainly in form of tablets and capsules.

EFFECT: obtained solid medication forms satisfy the requirements of the State Pharmacopoeia.

7 cl, 2 dwg, 3 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics, in particular a pharmaceutical composition in the form of a peroral drug form is described. The composition includes rebamipide as an active ingredient and a pharmaceutically acceptable carrier. Rebamipide is contained in an amount from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.

EFFECT: application of the rebamipide-based pharmaceutical composition for the prevention and treatment of arthrosoarthritis.

5 cl, 3 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: agent is presented in the form of a tablet, contains isoniazid and a substance which reduces its toxicity; as the substance which reduces the isoniazid toxicity, it contains thiotriazolin. The isoniazid/thiotriazolin ratio makes 4:1.

EFFECT: combined antituberculous drug ensures reducing toxicity as compared to the known ones and increasing its pharmacological activity.

2 cl, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention represents a pharmaceutical composition for treating the HIV infection in the form of a solid dosage form, containing at least one HIV protease inhibitor in a therapeutically effective amount specified in a group of nelfinavir, sacvinavir, tipranavir, darunavir, indinavir, ritonavir, lopinavir, palinavir or fosamprenavir, and pharmaceutically acceptable additives differing by the fact that as the pharmaceutically acceptable additives it contains at least one water-insoluble polymer from 0.39 to 28 wt % of the total dosage form, surfactants, excipients up to 100% of the total dosage form, as well as a method of treating the HIV infection.

EFFECT: pharmaceutical composition according to the invention possesses the improved technological properties and improved bioavailability as compared to a prototype therapeutic agent.

10 cl, 4 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, gynaecology, birth control techniques used as and when necessary, and emergency contraception. Ulipristal acetate or its metabolite is administered orally in a female no more than 72 hours to 120 hours after a sexual encounter in a dose of 20 to 30 mg. Another dose can be administered again at least twice a month. The preparation can be administered either in the form of an immediate-release dosage form, in the form of a tablet.

EFFECT: method provides the high efficacy of emergency contraception even in low doses and late administration of the preparation - up to 120 hours after the sexual encounter as compared to a reference preparation of levonorgestrel.

7 cl

FIELD: chemistry.

SUBSTANCE: presented is a group of inventions containing a solid dosage composition and a method for producing it. The solid dosage composition contains at least one pressed layer containing ibuprofen, microcrystalline cellulose and hydroxypropyl methylcellulose (HPMC) K100LV, HPMC K4M and combinations thereof, wherein HPMC is present in an amount of 10 to 30 wt % of the pressed layer, wherein viscosity of 2 wt/wt % of K100LV, HPMC K4M and a combination thereof makes 100 to 1414 sP, and wherein ibuprofen is subject to wet granulation. The method for producing the above composition involves pre-mixing ibuprofen by wet granulation with the above ingredients.

EFFECT: minimising the immediate release of ibuprofen ensured by producing the more stable gel matrix.

3 cl, 9 dwg, 2 tbl, 24 ex

FIELD: chemistry.

SUBSTANCE: coagglomerates of crystalline mannitol and granular starch in the ratio mannitol/starch from 99.5/0.5 to 50/50 have compressibility of 200 N to 450 N, flow time of 3 to 15 s and volume mean diameter D4.3 of particles based on laser granulometry of 60 to 500 mcm. The coagglomerates are intended for producing tablets or solid gelatin capsules for use in pharmaceutics. The method of producing said coagglomerates includes preparing, at 45-65°C, a solution of mannitol and granular starch or a mannitol solution only, where content of solid substance ranges from 25% to 45%, holding said solution at 45-65°C, spray-drying said solution in an MSD-type dryer equipped with a high pressure spray-drying nozzle with recycling of the fine particles at the spray-dryer top and, if necessary, adding dry starch, separating the obtained the coagglomerates of mannitol and of starch. The method can also include granulating the solution of mannitol and starch by spraying in a circular continuous fluidised-bed granulator with a discharge pipe or plug-flow rectangular continuous fluidised-bed granulator.

EFFECT: obtaining coagglomerates with good compressibility and good fluidity.

9 cl, 12 tbl, 8 ex

Drug // 2540509

FIELD: medicine.

SUBSTANCE: drug preparation contains a combination of phenylephrine hydrochloride (or an equivalent amount of the other pharmaceutically acceptable form of phenylephrine) and paracetamol.

EFFECT: combining two active ingredients provides effective relief of cold and influenza symptoms.

14 cl, 5 dwg, 4 ex, 10 tbl

FIELD: medicine.

SUBSTANCE: agent in the form of a vitamin complex applicable for replenishment of the deficiency of various nutrients in the body and in diseases related to the deficiency, as well as to prevent nausea and vomiting in the form of tablets exhibiting the therapeutic effect on nausea and vomiting of pregnancy, characterised by the fact that it contains ginger (Zingiber officinalis) in the form of dry extract of roots, folic acid, Vitamin B6, a pharmacologically acceptable calcium source and additives - sorbitol, magnesium stearate and silicon dioxide. What is also presented is a method for preparing it by granulating and drying in the certain environment and pressed.

EFFECT: agent represents the effective, easy-to-use vitamin additive with the therapeutic effect, which has the safe length of administration.

5 cl, 5 ex

FIELD: medicine.

SUBSTANCE: method implies using Cytoflavinum 10 ml in physiological saline 200 ml twice a day every 12 hours for 3 preoperative days and once intraoperatively. The above therapeutic regimen enables correcting endogenous intoxication effectively and compensating underlying respiratory disorders in the patients suffering colorectal cancer.

EFFECT: reducing rate and intensity of the respiratory disorders with underlying reduced degree of endogenous intoxication in the patients prior to the coming surgical management of colorectal cancer.

Up!